USPTO Examiner DACE DENITO ALEXANDRA GERALDINE - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18934005COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024November 2025Allow1220NoNo
18934041COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18896055COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024November 2025Allow1320NoNo
18743724RECOMBINANT PARTICLE PROTEIN PRODUCT SUITABLE FOR INDUSTRIAL PRODUCTION AND PREPARATION METHOD THEREFORJune 2024May 2025Allow1120YesNo
18653253SMALL INTERFERING RNA TARGETING CFB AND USES THEREOFMay 2024December 2025Abandon1930NoNo
18640396CONTAMINATION CONTROL WHEN GROWING GREEN ALGAEApril 2024August 2025Abandon1630NoNo
18607256Circular RNA For Translation In Eukaryotic CellsMarch 2024October 2025Allow1940YesNo
18604547Inducible Promoter for Rice Expression System, Synthetic Biological Platform and Use ThereofMarch 2024March 2025Allow1220NoNo
18544160Circular RNA For Translation In Eukaryotic CellsDecember 2023August 2025Allow2020NoNo
18532043CONTAMINATION CONTROL WHEN GROWING YEASTSDecember 2023January 2025Allow1350YesNo
18512068APPLICATION OF PROKARYOTIC ARGONAUTE PROTEIN WITH ONLY RNA TARGET CLEAVAGE ACTIVITY IN RNA EDITINGNovember 2023June 2024Allow710NoNo
18213116OLIGONUCLEOTIDESJune 2023June 2025Allow2421YesNo
18147119Use of CD56 to predict the differentiation potential of muscle stem cellsDecember 2022October 2024Abandon2220NoNo
18076638Modification of Gene Transcription and Translation Efficiency by 5'UTR Sequence VariationDecember 2022December 2023Allow1200YesNo
18060881COMPOSITIONS AND METHODS FOR MODULATING APOC3 EXPRESSIONDecember 2022October 2024Allow2311NoNo
17926383OLIGONUCLEOTIDESNovember 2022November 2025Abandon3611NoNo
17925871Compositions and Methods for Modifying Target RNAsNovember 2022March 2026Abandon4001NoNo
17857262Novel mutations in Streptococcus pyogenes Cas9 discovered by broad scanning mutagenesis demonstrate enhancement of DNA cleavage activityJuly 2022January 2025Allow3011NoNo
17774184METHODS OF MAKING CELLULAR THERAPIESMay 2022December 2025Abandon4410NoNo
17633778Compounds for Hepatitis B TreatmentFebruary 2022November 2025Abandon4501NoNo
17626581METHODS AND COMPOSITIONS FOR TREATING PULMONARY ARTERIAL HYPTERNSIONJanuary 2022October 2025Abandon4510NoNo
17617897NOVEL GENOME EDITING TOOLDecember 2021February 2026Abandon5111NoNo
17432361COMPOSITIONS AND METHODS TO TREAT BIETTI CRYSTALLINE DYSTROPHYAugust 2021July 2025Abandon4601NoNo
17431547RNA APTAMER THAT SPECIFICALLY BINDS HISTAMINEAugust 2021November 2025Abandon5111NoNo
17395011SYSTEMS AND METHODS OF USING CELL-FREE NUCLEIC ACIDS TO TAILOR CANCER TREATMENTAugust 2021June 2025Abandon4740NoNo
17427010Adeno-Associated Virus Delivery of CLN3 PolynucleotideJuly 2021April 2025Allow4510NoNo
17299377ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMSJune 2021March 2025Abandon4521NoNo
17294165METHOD FOR PRODUCING GENOME-EDITED CELLMay 2021March 2025Allow4620NoNo
17320664DELIVERY OF RNA TO DIFFERENT CELL TYPESMay 2021March 2025Abandon4610NoNo
17319546RNAI INDUCED REDUCTION OF ATAXIN-3 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3May 2021January 2025Abandon4401NoNo
17290187Methods of Treatment, Prevention and DiagnosisApril 2021January 2025Abandon4501NoNo
17289634COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONSApril 2021February 2026Abandon5721NoNo
17238872METHODS AND RELATED ASPECTS FOR QUANTITATIVE RATIOMETRIC REGRESSION POLYMERASE CHAIN REACTIONApril 2021August 2025Abandon5141YesNo
17276235RAMA TRANSCRIPTION FACTOR MUTANT FOR PROMOTING PRODUCTION OF N-ACETYLGLUCOSAMINE AND USE THEREOFMarch 2021March 2025Allow4820NoNo
17191864TALEN-BASED GENE CORRECTIONMarch 2021October 2024Abandon4401NoNo
17271037PHOTOACTIVATABLE TET EXPRESSION CONTROL SYSTEMFebruary 2021March 2025Allow4821NoNo
17270843DISSEMINATED NEOPLASIA CELLS AND METHODS OF THEIR USE TO CONTROL INVASIVE OR PEST SPECIESFebruary 2021August 2024Abandon4210NoNo
16980246NOVEL CRISPR DNA AND RNA TARGETING ENZYMES AND SYSTEMSJanuary 2021August 2024Allow4710NoNo
17147874METHODS OF DECREASING BACKGROUND ON A SPATIAL ARRAYJanuary 2021March 2025Allow5041YesNo
17259950DOUBLE KNOCK-OUT CHO CELL LINE METHOD OF ITS GENERATION AND PRODUCING THERAPEUTIC PROTEINS THEREFROMJanuary 2021October 2025Allow5721YesNo
16973353OPTIMIZING BAG3 GENE THERAPYDecember 2020August 2025Allow5731YesNo
17055842DIRECTED EVOLUTIONNovember 2020May 2024Abandon4201NoNo
16966567Gene Panel for Personalized Medicine, Method for Forming Same, and Personalized Treatment Method Using SameOctober 2020October 2024Abandon5121NoNo
17025259GENE REGULATION VIA CONDITIONAL NUCLEAR LOCALIZATION OF GENE MODULATING POLYPEPTIDESSeptember 2020July 2025Abandon5821NoNo
16980825VIRAL VECTOR PRODUCTION SYSTEMSeptember 2020October 2024Abandon4911NoNo
17020414NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMSSeptember 2020February 2026Allow6030YesNo
17020215NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMSSeptember 2020January 2026Abandon6010NoNo
16840103METHODS FOR DETERMINING FRACTION OF FETAL NUCLEIC ACIDS IN MATERNAL SAMPLESApril 2020June 2024Allow5110NoNo
16648885NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLSMarch 2020June 2023Abandon3921NoNo
16432177CIRCULAR RNA FOR TRANSLATION IN EUKARYOTIC CELLSJune 2019December 2023Allow5521YesNo
14786637METHOD FOR A CELL-BASED DRUG SCREENING ASSAY AND THE USE THEREOFOctober 2015December 2024Abandon60110YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DACE DENITO, ALEXANDRA GERALDINE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DACE DENITO, ALEXANDRA GERALDINE - Prosecution Strategy Guide

Executive Summary

Examiner DACE DENITO, ALEXANDRA GERALDINE works in Art Unit 1636 and has examined 30 patent applications in our dataset. With an allowance rate of 36.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.

Allowance Patterns

Examiner DACE DENITO, ALEXANDRA GERALDINE's allowance rate of 36.7% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DACE DENITO, ALEXANDRA GERALDINE receive 1.93 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DACE DENITO, ALEXANDRA GERALDINE is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +45.3% benefit to allowance rate for applications examined by DACE DENITO, ALEXANDRA GERALDINE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.0% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.0% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.